Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
The Motley Fool December 2, 2010 Brian Orelli	An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
BusinessWeek February 19, 2007 Gene G. Marcial	Will Healthy Lab Data Revive Ailing Cell Genesys? Cell genesys is in the midst of clinical trials of vaccines for prostate and pancreatic cancer that analysts believe should catch investors' eyes.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool January 12, 2004 Dave Marino-Nachison	All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials.
AskMen.com	Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range.
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool January 11, 2005 Charly Travers	The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease?
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
American Family Physician May 15, 2005	Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options.
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
AskMen.com Jacob Franek	Prostate Cancer Treatment And Prevention Everything you wanted to know about prostate cancer in our three-part Prostate Cancer Guide.
AskMen.com Jen Woodward	Prostate Cancer 101 Here are some of the basic facts about prostate cancer, along with what you can do to keep the C-word from gracing your medical chart.
The Motley Fool August 23, 2005 W.D. Crotty	A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look?
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
AskMen.com Jacob Franek	Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide.
BusinessWeek August 15, 2005	Misonix Zaps Prostate Cancer Misonix, a maker of medical and scientific gear, has investors interested in its new ultrasound device for prostate cancer. Shares have risen from $5.22 on Apr. 18 to $6.50 on Aug. 3.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
Nurse Practitioner October 2009 Wallace et al.	Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education.
AskMen.com Jacob Franek	Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease.
AskMen.com Alex Santoso	Prostate Health 101 Most men don't have any clue about their prostate -- until things go wrong. With this information, they can maximize their prostate health.
ifeminists October 15, 2002 Sacks & Thompson	When Men's Health Doesn't Count Congress is sending a message to American men: men's health doesn't count.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
AskMen.com	Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good.
Salon.com April 28, 2000 Dawn MacKeen	A disease fueled by testosterone When a politician announces he has prostate cancer, what does it mean?
Chemistry World February 11, 2009 Lewis Brindley	Prostate Cancer Biomarker Could Speed Diagnosis US researchers have identified a compound in urine that could be used to detect prostate cancer - and also to distinguish between benign and invasive forms of the disease.
American Family Physician September 15, 2005 Mark H. Ebell	Point-of-Care Guides What is the risk of prostate cancer in a patient who is referred for biopsy?
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
AskMen.com Jacob Franek	4 Fun Ways To Help Prevent Prostate Cancer We're not pretending that there's anything fun about prostate cancer. We are attempting to encourage men to take measures to prevent the disease.
AskMen.com April 15, 2014 Naomi Mead	Don't Put Your Sexual Health At Risk! Eat These 5 Foods Right Now & Protect Yourself. It is believed that a high-sugar, high-fat, processed Western diet may have a significant part to play in the increased rates of prostate cancer we are now observing.
AskMen.com May 27, 2002 David Dixon	Important Information About Your Prostate Read on to learn about what men can do to protect themselves from this silent but deadly killer...
AskMen.com March 17, 2001 Joshua Levine	The Importance Of Regular Check-Ups For Men Men are much less likely than women to seek the routine medical care that they should. This article describes some of the risks.
Nutra Solutions January 1, 2005 Kerry Hughes	Ingredients to Reduce Cancer Risks Approximately 35% of cancer deaths in the U.S. can be prevented by dietary means. Scientific evidence shows that properly balancing fruits, vegetables, dietary fiber, antioxidants, vitamins, minerals and certain dietary supplements protects our health.
American Family Physician May 15, 2005 Bhatnagar & Kaplan	Treatment Options for Prostate Cancer: Evaluating the Evidence Controversy surrounds the management options for localized prostate cancer-conservative management, prostatectomy, and radiation. Choosing among these options is difficult because of long-term side effects that include sexual, urinary, and bowel dysfunction.
Salon.com September 20, 2000 Cathy Young	Medical gender wars First came the whining feminists. Next, the inevitable male backlash. Health research has become a casualty of the battle between the sexes.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
American Family Physician August 15, 2001 Rosemarie Sweeney & Matthew Neff	Newsletter Guidance Issued on New Federal Protection Rules on Patient Privacy... Participants Are Needed for Prostate Cancer Prevention 'SELECT' Trial... Document Compares Five Federal Prescription Drug Coverage Proposals... etc.
American Family Physician May 1, 2002 Ramsis Benjamin	Neurologic Complications of Prostate Cancer Neurologic complications continue to pose problems in patients with metastatic prostate cancer...